Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02118298 · ClinicalTrials.gov registry record

Allocentric Memory in MS and Resting State Functional MRI

A clinical trial of Multiple Sclerosis, sponsored by Yale University.

Completed
Registry status
120
Enrollment target
1
Study location

NCT02118298: Completed study of Multiple Sclerosis, sponsored by Yale University.

NCT02118298 is a study of Multiple Sclerosis that has completed, run by Yale University. The registered enrollment target is 120 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02118298, a study of Multiple Sclerosis, has completed, sponsored by Yale University.

COMPLETED
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls. 2. Determine which cognitive test variable will be most strongly associated with self and informant reports of cognition. 3. Determine which MRI metric will be most strongly related to neuropsychological test performance 4. Determine the degree to which allocentric visual memory is related to functional connectivity on fMRI.

Primary Outcome

The MACFIMS is composed of seven neuropsychological tests, covering five cognitive domains commonly impaired in MS (processing speed/working memory, learning and memory, executive function, visual-spatial processing and word retrieval)

Conditions Studied

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2014-04
Est. Completion 2016-04
Yale University

1,492 total trials

What the finished NCT02118298 record still lists

NCT02118298 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT02118298 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT02118298 about?

NCT02118298 is a clinical study titled "Allocentric Memory in MS and Resting State Functional MRI". The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls. 2. Determine which cognitive test variable will be most strongly assoc...

What is the current status of trial NCT02118298?

This trial is currently completed. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2016-04.

What conditions does trial NCT02118298 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT02118298?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02118298 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02118298's enrollment target sits among peer trials

120 111th of 315 higher than 197 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02118298, the US trial registry maintained by the National Library of Medicine. NCT02118298 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.